Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance

Monica Nolan, Mary Glenn Fowler, Lynne M. Mofenson

Research output: Contribution to journalArticle

Abstract

Since 1994, trials of zidovudine, zidovudine and lamivudine, and nevirapine have demonstrated that these antiretroviral drugs can substantially reduce the risk of perinatal HIV-1 transmission. With reductions in drug price, identification of simple, effective antiretroviral regimens to prevent perinatal HIV-1 transmission, and an increasing international commitment to support health care infrastructure, antiretrovirals for both perinatal HIV-1 prevention and HIV-1 treatment will likely become more widely available to HIV-1-infected persons in resource-limited countries. In the United States, widespread antiretroviral usage has been associated with increased antiretroviral drug resistance. This raises concern that drug resistance may reduce the effectiveness of perinatal antiretroviral prophylaxis as well as therapeutic intervention strategies. The purpose of this article is to review what is known about resistance and risk of perinatal HIV transmission, assess the interaction between antiretroviral resistance and the prevention of perinatal HIV-1 transmission, and discuss implications for current global prevention and treatment strategies.

Original languageEnglish (US)
Pages (from-to)216-229
Number of pages14
JournalJournal of Acquired Immune Deficiency Syndromes
Volume30
Issue number2
StatePublished - Jun 1 2002
Externally publishedYes

Fingerprint

HIV-1
Zidovudine
Drug Resistance
Nevirapine
Lamivudine
Pharmaceutical Preparations
HIV
Delivery of Health Care
Therapeutics

Keywords

  • Antiretroviral
  • Perinatal HIV transmission
  • Prevention
  • Resistance
  • Treatment

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. / Nolan, Monica; Fowler, Mary Glenn; Mofenson, Lynne M.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 30, No. 2, 01.06.2002, p. 216-229.

Research output: Contribution to journalArticle

@article{117b38960bdc4a238f5089b998a68ab4,
title = "Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance",
abstract = "Since 1994, trials of zidovudine, zidovudine and lamivudine, and nevirapine have demonstrated that these antiretroviral drugs can substantially reduce the risk of perinatal HIV-1 transmission. With reductions in drug price, identification of simple, effective antiretroviral regimens to prevent perinatal HIV-1 transmission, and an increasing international commitment to support health care infrastructure, antiretrovirals for both perinatal HIV-1 prevention and HIV-1 treatment will likely become more widely available to HIV-1-infected persons in resource-limited countries. In the United States, widespread antiretroviral usage has been associated with increased antiretroviral drug resistance. This raises concern that drug resistance may reduce the effectiveness of perinatal antiretroviral prophylaxis as well as therapeutic intervention strategies. The purpose of this article is to review what is known about resistance and risk of perinatal HIV transmission, assess the interaction between antiretroviral resistance and the prevention of perinatal HIV-1 transmission, and discuss implications for current global prevention and treatment strategies.",
keywords = "Antiretroviral, Perinatal HIV transmission, Prevention, Resistance, Treatment",
author = "Monica Nolan and Fowler, {Mary Glenn} and Mofenson, {Lynne M.}",
year = "2002",
month = "6",
day = "1",
language = "English (US)",
volume = "30",
pages = "216--229",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance

AU - Nolan, Monica

AU - Fowler, Mary Glenn

AU - Mofenson, Lynne M.

PY - 2002/6/1

Y1 - 2002/6/1

N2 - Since 1994, trials of zidovudine, zidovudine and lamivudine, and nevirapine have demonstrated that these antiretroviral drugs can substantially reduce the risk of perinatal HIV-1 transmission. With reductions in drug price, identification of simple, effective antiretroviral regimens to prevent perinatal HIV-1 transmission, and an increasing international commitment to support health care infrastructure, antiretrovirals for both perinatal HIV-1 prevention and HIV-1 treatment will likely become more widely available to HIV-1-infected persons in resource-limited countries. In the United States, widespread antiretroviral usage has been associated with increased antiretroviral drug resistance. This raises concern that drug resistance may reduce the effectiveness of perinatal antiretroviral prophylaxis as well as therapeutic intervention strategies. The purpose of this article is to review what is known about resistance and risk of perinatal HIV transmission, assess the interaction between antiretroviral resistance and the prevention of perinatal HIV-1 transmission, and discuss implications for current global prevention and treatment strategies.

AB - Since 1994, trials of zidovudine, zidovudine and lamivudine, and nevirapine have demonstrated that these antiretroviral drugs can substantially reduce the risk of perinatal HIV-1 transmission. With reductions in drug price, identification of simple, effective antiretroviral regimens to prevent perinatal HIV-1 transmission, and an increasing international commitment to support health care infrastructure, antiretrovirals for both perinatal HIV-1 prevention and HIV-1 treatment will likely become more widely available to HIV-1-infected persons in resource-limited countries. In the United States, widespread antiretroviral usage has been associated with increased antiretroviral drug resistance. This raises concern that drug resistance may reduce the effectiveness of perinatal antiretroviral prophylaxis as well as therapeutic intervention strategies. The purpose of this article is to review what is known about resistance and risk of perinatal HIV transmission, assess the interaction between antiretroviral resistance and the prevention of perinatal HIV-1 transmission, and discuss implications for current global prevention and treatment strategies.

KW - Antiretroviral

KW - Perinatal HIV transmission

KW - Prevention

KW - Resistance

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0036603048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036603048&partnerID=8YFLogxK

M3 - Article

C2 - 12045685

AN - SCOPUS:0036603048

VL - 30

SP - 216

EP - 229

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 2

ER -